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Abstract Sjo ¨gren–Larsson syndrome is a genetic disease
characterized by ichthyosis, mental retardation, spasticity
and mutations in the ALDH3A2 gene coding for fatty
aldehyde dehydrogenase, an enzyme necessary for oxida-
tion of fatty aldehydes and fatty alcohols. We investigated
the cutaneous abnormalities in 9 patients with Sjo ¨gren–
Larsson syndrome to better understand how the enzymatic
deﬁciency results in epidermal dysfunction. Histochemical
staining for aldehyde oxidizing activity was profoundly
reduced in the epidermis. Colloidal lanthanum perfusion
studies showed abnormal movement of tracer into the
extracellular spaces of the stratum corneum consistent with
a leaky water barrier. The barrier defect could be attributed
to the presence of abnormal lamellar bodies, many with
disrupted limiting membranes or lacking lamellar contents.
Entombed lamellar bodies were present in the cytoplasm of
corneocytes suggesting blockade of lamellar body secre-
tion. At the stratum granulosum–stratum corneum inter-
face, non-lamellar material displaced or replaced secreted
lamellar membranes, and in the stratum corneum, the
number of lamellar bilayers declined and lamellar mem-
brane organization was disrupted by foci of lamellar/non-
lamellar phase separation. These studies demonstrate the
presence of a permeability barrier abnormality in Sjo ¨gren–
Larsson syndrome, which localizes to the stratum corneum
interstices and can be attributed to abnormalities in
lamellar body formation and secretion.
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Introduction
Sjo ¨gren–Larsson syndrome (SLS) is a rare, autosomal
recessive disorder characterized by ichthyosis, mental
retardation and spastic diplegia or tetraplegia [26, 35]. The
ichthyosis is usually apparent at birth and often has a mild
erythematous appearance that fades over time [21]. A
collodion membrane is rarely seen. Pruritus is a common
complaint in infants and older patients. Developmental
delay and spasticity develop over the ﬁrst 2 years [12] and
white matter changes are typically seen on brain imaging
[36, 40]. Many patients have photophobia and exhibit
glistening white dots on the retina [37]. Patients typically
survive into adulthood.
Sjo ¨gren–Larsson syndrome (SLS) is caused by muta-
tions in the ALDH3A2 gene that encodes fatty aldehyde
dehydrogenase (FALDH) [2], an enzyme that catalyzes the
oxidation of aliphatic aldehydes to fatty acids [17, 29].
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DOI 10.1007/s00403-009-1022-yDespite knowing the enzymatic defect in SLS, the patho-
genic mechanisms resulting in ichthyosis have been elusive
[27]. FALDH acts on several aliphatic aldehydes, but no
single lipid has been identiﬁed yet as central to the path-
ogenesis. Fatty aldehydes and their precursor lipids, such as
fatty alcohols [30] and leukotriene B4 [38, 39], accumulate
in tissues of SLS patients. In cultured SLS keratinocytes,
impaired oxidation of fatty alcohols (C16 and C18) leads to
their metabolic diversion into biosynthetic pathways for
wax esters and neutral ether glycerolipids, which conse-
quently accumulate [31]. FALDH is also involved in x-
oxidation of very-long-chain fatty acids [32]. These lipid
abnormalities, or others yet to be identiﬁed in SLS, may
contribute to the cutaneous symptoms.
Defects in lipid metabolism underlie many of the
ichthyoses, including neutral lipid storage disease with
ichthyosis (Chanarin–Dorfman syndrome), X-linked ich-
thyosis, Refsum disease, Harlequin ichthyosis and several
forms of autosomal recessive congenital ichthyosis [7].
Since the lipid composition of the stratum corneum (SC)
membranes is critical for maintaining the epidermal water
barrier, certain alterations in SC membrane formation or
lipid composition appear to provoke a leaky barrier, which
in turn ‘drives’ the ichthyosiform dermatosis [4]. Impor-
tantly, with the exception of Harlequin ichthyosis, lamellar
body formation and secretion are not impaired. Instead,
most of these lipid metabolic disorders have in common
lamellar/non-lamellar phase separation as the basis for the
permeability barrier abnormality [7]. To date, neither bar-
rier function nor SC membrane formation have been
assessed in SLS.
Membranes destined for the SC are synthesized in stra-
tum granulosum (SG) cells and packaged within the trans-
Golgi network into lamellar bodies (LB) [5], which then
fuse with the apical plasma membrane of the outermost SG
cell, releasing their lamellar contents into the SC interstices
[22]. In normal epidermis, LB secretion results in the
transfer of all lamellar body contents to the extracellular
spaces, leaving corneocytes devoid of lipids [6]. The
deposited LB lipids are subsequently processed into a
hydrophobic, equimolar mixture of ceramides, free fatty
acids and cholesterol that self-assembles into mature SC
membranes. Prior reports of isolated patients with SLS have
described membranous lipid inclusions in the cytosol of SG
cells and within corneocytes [11, 23], as well as structurally
abnormal LB [34]. Nevertheless, whether these features are
simply disease markers, or are important for the patho-
genesis of the epidermal abnormalities in SLS is not known.
Here, we investigated a group of SLS patients with the
aim of further deﬁning the link between genetic defect and
clinical phenotype by focusing on the functional and
structural abnormalities that contribute to ichthyosis. Since
the cutaneous phenotype in all other ichthyoses studied to
date likely reﬂects a metabolic response to an underlying
permeability barrier abnormality, we began with an
assessment of barrier function in SLS, followed by an
assessment of the cellular pathogenesis of the barrier
abnormality. Our ﬁndings indicate that the ichthyosis in
SLS is associated with a barrier abnormality that is not only
characterized by structurally defective SC lamellar mem-
branes, but also by a global defect in LB formation and
secretion.
Materials and methods
Patients
Sjo ¨gren–Larsson syndrome (SLS) patients were diagnosed
based on their clinical features, deﬁcient FALDH enzyme
activity and the presence of ALDH3A2 mutations. Patients
#1 and #2 are siblings who have been previously reported
[20]. Patients #7 and #8 are also siblings; other patients are
single probands from unrelated families. This human
research was approved by the Institutional Review Boards
at the University of Nebraska Medical Center, Medical
College of Virginia of Virginia Commonwealth University
and University of California, San Francisco. Informed
consent was obtained from all subjects or, in the case of
minors, from their parents.
Mutation analysis
Genomic DNA was isolated from blood or cultured skin
ﬁbroblasts using standard methods. ALDH3A2 exons were
ampliﬁed by PCR as described [28]. Mutations were
detected by directly sequencing the ampliﬁed exons using
the BigDye Terminator cycle Sequencing Kit (Applied
Biosystems, Inc., Foster City, CA) and ABI 377A sequen-
cer. Mutations were identiﬁed by comparison to the Gen-
Bank sequence of ALDH3A2(accessionNM_000382.1) and
designated using the cDNA numbering system.
Enzymatic studies
Cultured skin ﬁbroblasts were established from skin bio-
psies and grown as described [29]. Cells were harvested
and FALDH activity was measured using octadecanal as
substrate [29]. Enzyme activity was expressed as pmol
octadecanal oxidized/min/mg cell protein.
Light and electron microscopy
Skin punch biopsies were ﬁxed with glutaraldehyde and
post-ﬁxed in osmium tetroxide or ruthenium tetroxide,
followed by dehydration and embedding in an Epon–epoxy
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123mixture or in lipid-retaining resin-white as described [3].
To evaluate permeability barrier dysfunction, the skin
biopsies from two SLS patients were immersed in 4%
colloidal lanthanum, a water-soluble electron-dense tracer,
for at least 1 h prior to osmium tetroxide post-ﬁxation and
Epon/epoxy embedding as described [5, 33]. Ultrathin
sections were examined with a Zeiss 10A electron micro-
scope operated at 60 kV.
Histochemical staining for aldehyde oxidizing activity
Skin punch biopsies were obtained from the upper arm and
immediately frozen in optimal cutting temperature com-
pound using dry ice. The tissues were sectioned at 16 lm
and kept frozen at -70C until use. Each slide contained
sections of skin from SLS and control subjects. Aldehyde
oxidizing activity was detected according to Judge et al.
[16] except sections were not acetone-extracted and 8 mM
octanal was used as substrate. The slides were incubated at
37C in 50 mM Tris–HCl buffer, pH 8.5 containing
3.0 mM NAD?, 16 mM cobaltous chloride, 0.33 mg/ml
MTT and 8.0 mM octanal. After 1–3 h, the slides were
rinsed twice in water for 5 min each and mounted in
glycerin. Slides were examined by light microscopy and
photographed.
Detection of apoptotic cells
Cells undergoing apoptosis were detected in skin biopsy
sections by TdT-mediated dUTP nick end labeling
(TUNEL) using the In Situ Cell Death Detection Kit
(Roche Applied Science, Indianapolis, IN) according to the
manufacturer’s instructions. TUNEL positive cells in the
SG were quantitated by photographing sections at 209
magniﬁcation and counting the stained cells in the ﬁeld of
view.
Results
We studied 9 SLS patients from 7 unrelated families
(Table 1). The patients ranged from 1 year of age to
34 years. All patients had generalized hyperkeratosis and
neurologic symptoms that are typical of SLS, along with
diagnostic reductions in ﬁbroblast FALDH activity (2–16%
of normal). DNA analysis demonstrated mutations in the
ALDH3A2 gene in all patients. Eight patients had homo-
zygous mutations, whereas one patient (#3) was a com-
pound heterozygote who carried one common ALDH3A2
mutation (c.1297_1298delGA) and a presumptive second
unidentiﬁed mutation (Table 1).
Light microscopy of the skin showed epidermal hyper-
plasia with prominent hyperkeratosis, papillomatosis and
spongiosis (Fig. 1a). The SC was thickened and appeared
more dense and compact in regions close to the SG. The
granular layer tended to be normal in size (Fig. 1b). Nei-
ther the SC nor the SG stained with oil red O, suggesting
that large amounts of neutral lipid do not accumulate in
SLS (not shown). In one SLS patient examined (patient
#8), the number of SG cells staining positive with TdT-
Table 1 Sjo ¨gren–Larsson syndrome patients studied
Patient Age (years)/Sex Fibroblast FALDH
activity (% of control
c)
ALDH3A2 genotype Investigations performed
1
a 32/M 5 c.798?5_798?6del/
c.798?5_798?6del
EM: OsO4, RuO4
d
2
a 34/F 4 c.798?5_798?6del/
c.798?5_798?6del
EM: OsO4, RuO4
3 5/M 9 c.1297_1298delGA/? EM: OsO4, RuO4
4 4/M 3 c.798?5G[A/c.798?5G[A EM: OsO4, RuO4
5 3/F 7 c.798?1delG/c.798?1delG EM: OsO4, RuO4
6 1/M 7 c.710G[A/c.710G[A EM: OsO4, RuO4
7
b 21/M 13 c.1297_1298delGA/
c.1297_1298delGA
Lanthanum perfusion
8
b 19/F 16 c.1297_1298delGA/
c.1297_1298delGA
Histochemical staining, TUNEL
9 15/F 2 c.710G[A/c.710G[A Lanthanum perfusion
a Siblings in family 1
b Siblings in family 2
c Control FALDH activity was 8,860 ± 1,624 pmol/min/mg protein (n = 22)
d Electron microscopy with osmium tetroxide and ruthenium tetroxide post-ﬁxation
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123mediated dUTP nick end labeling (TUNEL), a marker
for apoptosis, were increased by 80% compared to a
normal control (SLS: 18 ± 3 cells/ﬁeld, n = 7; control:
10 ± 3 cells/ﬁeld, n = 7).
Aldehyde oxidizing activity in skin was visualized using
a histochemical staining method with octanal as substrate
(Fig. 2). Normal skin showed abundant staining of the
epidermis and there was scattered staining of dermal
ﬁbroblasts (Fig. 2a). The SC displayed no enzyme activity.
Staining was dependent on the presence of octanal
(Fig. 2c) and was completely inhibited by the addition of
10 mM disulﬁram, which is an aldehyde dehydrogenase
inhibitor (data not shown). In contrast to normal skin, SLS
skin showed a profound lack of enzyme activity throughout
the epidermis and dermis (Fig. 2b).
To evaluate the integrity of the epidermal water barrier
in SLS, we perfused freshly obtained skin biopsies from 2
SLS patients (patients #7 and #9) with colloidal lanthanum
nitrate prior to OsO4 post-ﬁxation. Lanthanum is a low-
molecular weight, water-soluble, electron-dense tracer that
is normally excluded from entry into the SC. In the SLS
skin samples, however, the tracer moved outward beyond
the SG, and entered the SC interstices (Fig. 3). Since tracer
did not enter corneocytes, a defect in corneocyte integrity
can be excluded as the cause of the permeability barrier
abnormality in SLS. These ﬁndings indicate accelerated,
paracellular traverse of water, with further localization of
the permeability barrier abnormality to the SC extracellular
domains.
Next we assessed the cellular basis for the permeability
barrier abnormality in SLS. Skin biopsies from 6 SLS
patients (patients #1–#6) were examined by electron
microscopy using standard methods with post-ﬁxation in
osmium tetroxide and also ruthenium tetraoxide, which
allows better visualization of SC lipid membranes. The
SLS skin revealed normal numbers (i.e., density) of LB in
the SG, but individual organelles exhibited several struc-
tural abnormalities. Some LB appeared empty or contained
non-lamellar contents, whereas many others displayed
disrupted or absent limiting membranes (Fig. 4). The latter
feature has not yet been described in other lipid metabolic
disorders associated with ichthyosis [7]. At the SG–SC
interface, non-lamellar material displaced or replaced the
normal lamellar contents (Fig. 5). Unsecreted LB accu-
mulated at the outer periphery of SG cells and became
entombed in the corneocyte cytosol (Figs. 6, 7). This
ﬁnding suggests that secretion of LB at the SG–SC border
is impaired, due to defective LB fusion with the outer SG
Fig. 1 Histopathology of SLS.
a At low magniﬁcation,
epidermal hyperplasia,
spongiosis, and prominent
hyperkeratosis are evident in
patient #4. Note compactness of
lower SC (solid arrow) and
loosely organized mid- to upper-
SC (open arrows). b At higher
magniﬁcation, the granular layer
(arrows) is normal in size. Epon
embedded, 1 lm section,
toluidine blue staining
Fig. 2 Histochemical staining
for aldehyde (octanal) oxidizing
activity in normal and SLS skin.
a Normal skin shows abundant
staining of the epidermis, but
not of the SC. b SLS skin
(patient #8) has a profound
reduction in enzyme activity in
the epidermis. c Control
showing normal skin incubated
without octanal
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123plasma membrane. In the SC, lamellar domains were
interspersed with lacunae ﬁlled with non-lamellar mate-
rial, indicating lamellar/non-lamellar phase separation
(Fig. 7a), a structural feature of other lipidoses associated
with ichthyosis [7]. The structurally abnormal LB and
failure of LB secretion were further associated with a
paucity of lamellar bilayers in the SC (Fig. 7b). In contrast,
the corniﬁed lipid envelope appeared normal (Fig. 5a, c).
The structural abnormalities in SG and SC were
observed in all SLS patients studied. There was no apparent
relationship between the severity of the structural abnor-
malities and age of the patient, ALDH3A2 genotype or
residual enzyme activity measured in ﬁbroblasts.
Fig. 3 Lanthanum perfusion demonstrates a leaky epidermal water
barrier in SLS (patient #7). a Lanthanum tracer, which reﬂects the
pathway of water movement and is completely excluded from the SC
in normal skin, but breaches the SC via the extracellular spaces in
SLS (arrows). b Tracer moves outward through SG (curved arrow)
and remains restricted to SC interstices (a, arrows). a, b, osmium
tetroxide and ruthenium tetroxide post-ﬁxation
Fig. 4 Abnormal lamellar bodies in SLS. a–c Although the number
(density) of lamellar bodies appears normal in SLS, many organelles
appear empty (asterisks) or display non-lamellar contents. Moreover,
the limiting membrane of many individual organelles appears
disrupted or absent (arrows). Osmium tetroxide post-ﬁxation. a, c
Patient #4. b Patient #3
Fig. 5 Secretion of non-lamellar contents at stratum corneum (SC)—
stratum granulosum (SG) interface in SLS (patient #4). a–c Much of
the SG–SC interface is occupied by non-lamellar contents (asterisks)
that displace or replace secreted lamellar material. However, the
corniﬁed lipid envelope appears normal. Osmium tetroxide post-
ﬁxation
Fig. 6 Abnormal lamellar body secretion in SLS results in entomb-
ment of organelle contents in corneocytes. a, b Unsecreted organelles
become entombed in the corneocyte cytosol (a asterisks; b arrow)o f
patient #4. c Note the increased concentration of unsecreted lamellar
bodies (arrows) at the periphery of outer SG cells in patient #3. a, b,
ruthenium tetroxide post-ﬁxation; c osmium tetroxide post-ﬁxation
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Although a defective epidermal water barrier has been
presumed to exist in SLS, we provide the ﬁrst experimental
evidence for a barrier abnormality; i.e., the demonstration
of unimpeded paracellular traverse of colloidal lanthanum
between SC corneocytes. The basis for the barrier abnor-
mality is likely twofold. First, our studies demonstrate a
widespread disruption in the formation and secretion of LB
in the epidermis of SLS patients. The striking abnormalities
in LB structure included empty vesicles, inclusion of
amorphous material instead of the usual stacked mem-
branes and the presence of LB that have disrupted, or even
absent, vesicle membranes. The latter ﬁnding suggests that
the organelle limiting membrane is damaged after LB has
packaged their lipid and non-lipid contents. We interpret
our ﬁnding of unsecreted LB at the outer periphery of SG
cells and the entombment of LB in the cytoplasm of cor-
neocytes to arise from defective vesicle–plasma membrane
fusion, perhaps reﬂecting defects in the organelle limiting
membrane. The second reason for the putative barrier
abnormality is the paucity and disorganization of SC
lamellar membranes, a previously unrecognized structural
feature of SLS that was revealed with ruthenium tetroxide
post-ﬁxation. Decreased lamellar arrays correlate with the
impairment in LB secretion, noted above. But the lamellar
domains in the SC are interspersed with lacunae ﬁlled with
non-lamellar material, which reﬂects a process of lamellar/
non-lamellar phase separation in the SC similar to several
other forms of ichthyosis associated with defective lipid
metabolism [7]. Lamellar/non-lamellar phase separation
likely also reﬂects the lipid metabolic abnormality; i.e., the
critical ratio of cholesterol, free fatty acids and ceramides
is altered sufﬁciently to prevent incorporation of all
secreted lipids within lamellar arrays.
The ichthyosis in SLS is associated with a hyperprolif-
erative epidermal state as demonstrated by radioactive
thymidine incorporation [13] and our ﬁnding of an
increased number of apoptotic cells in the SG.
The ultrastructural abnormalities that we observed were
present in all 6 SLS patients examined. We found no
relationship between the severity of structural abnormali-
ties in the skin and the patients’ ages. Indeed, the clinical
appearance of the ichthyosis in SLS does not typically
change after infancy. Nor did the structural abnormalities
correlate with ALDH3A2 genotype or residual enzyme
activity in ﬁbroblasts. Most mutations are completely
destructive to FALDH catalytic activity [28], and the var-
iation in residual enzyme activity measured in cultured
ﬁbroblasts largely reﬂects the presence of other aldehyde
dehydrogenase enzymes that have some ability to oxidize
long-chain fatty aldehydes [26].
Defective LB vesicle membranes and impaired LB
secretion have not been previously recognized in SLS, but
ultrastructural abnormalities have been reported. Similar to
our patients here, Shibaki et al. [34] found empty LB, and
the presence of irregular granular material and lipid vac-
uoles in the intercellular domain between corneocytes in 2
Japanese SLS siblings with ALDH3A2 mutations. In an
atypical 5-year-old Japanese patient with low-normal
intelligence, mild neurologic symptoms and unusually late
onset of ichthyosis at 1 year of age, Ito et al. [11] found
membranous lipid inclusions in the cytoplasm of spinous
and granular cells and in corneocytes. Some LB appeared
misshapen and contained ﬁne granular or globular contents.
This patient was subsequently conﬁrmed to have FALDH
deﬁciency (Rizzo, unpublished). Membranous cytoplasmic
inclusions in corneocytes were observed in 2 additional
patients who were clinically diagnosed with SLS, but did
not have enzymatic or genetic conﬁrmation of the diag-
nosis [23].
The LB abnormalities seen in the SG, together with the
paucity of SC membranes and presence of lacunae
Fig. 7 Decreased lamellar bilayers and lamellar/non-lamellar phase
separation in SC interstices of patient #4. a, b Entombed lamellar
contents in corneocyte cytosol is evident (open arrows). Lamellar
domains are interspersed with lacunae ﬁlled with non-lamellar
material (asterisks). b Blockade of secretion (c.f., Fig. 6) also results
in paucity of lamellar bilayers (arrows). a, b ruthenium tetroxide
post-ﬁxation
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123containing non-membrane material are consistent with a
defect in lipid metabolism, but the precise lipids respon-
sible for the cutaneous pathology remain to be identiﬁed
[27]. Several candidate lipids may have speciﬁc deleterious
effects at different points in SC membrane formation, i.e.,
early in LB vesicle membrane formation, packaging of LB
membranes destined for the SC, or at the point of LB
exocytosis. Straight-chain fatty alcohols (C16:0 and
C18:0), wax esters and neutral ether glycerolipids (alkyl-
diacylglycerol) accumulate in cultured SLS keratinocytes
[31]. These lipids are non-polar and their accumulation in
granulosum cells could interfere at any point in LB for-
mation and secretion, or contribute to the lamellar/non-
lamellar phase separation seen in the SC. Failure to detect
histological evidence of neutral lipid accumulation by oil
red O staining of the SLS skin may reﬂect dispersion of
these neutral lipids in SG and SC membranes or insufﬁ-
cient sensitivity of the stain. Oil red O staining is usually
reserved for ichthyoses associated with accumulation of
cytoplasmic lipid droplets, i.e., neutral lipid storage disease
and Refsum disease. Alternately, other more polar lipids
may be responsible for the epidermal dysfunction. Oxida-
tion of isoprenoid alcohols, such as farnesol and gera-
nylgeraniol, has recently been found to be defective in
cultured skin ﬁbroblasts and in the epidermis of SLS
patients (Roullet J-B, Steiner R, Rizzo WB, unpublished
data). Farnesol induces keratinocyte differentiation in vitro
via a PPAR-a dependent mechanism [9]. It also impacts
cholesterol biosynthesis by hastening degradation of HMG-
CoA reductase [24] and inhibiting mevalonate kinase [10],
which raises the possibility that biosynthesis of epidermal
cholesterol, a major lipid of SC membranes, may be
reduced in SLS. Rodents treated with topical HMG-CoA
reductase inhibitors, such as lovastatin, exhibit abnormal
LB structures, including empty LB, and a defective epi-
dermal water barrier [8, 25]. FALDH is also involved in the
x-oxidation of at least 2 additional lipids: very-long-chain
fatty acids [32] and the inﬂammatory mediator leukotriene
B4 [38, 39]. Accumulation of leukotriene B4 seems to
contribute to the pruritus seen in SLS [38], but is unlikely
to affect the epidermal water barrier.
Recently, it has been speculated that FALDH might be
involved in metabolism of 12R-eicosanoids derived from
arachidonic acid, a lipid pathway that has emerged as crit-
ical for normal epidermal function. Two genes in this
pathway, ALOX12 and eLOX3, encode enzymes that
sequentially metabolize arachidonic acid to the epoxyal-
cohol 12R-hepoxilin A3 [1]. Mutations in ALOX12 and
eLOX3 are responsible for two forms of autosomal reces-
sive congenital ichthyosis, which strongly implies that 12R-
hepoxilin A3 or its downstream metabolite(s) are necessary
for normal barrier function [15]. Furthermore, mutations in
two additional genes (CYP4F22 and ichthyin) that encode a
putative x-hydroxylase enzyme and a putative membrane
receptor for 12R-epoxyalcohols, respectively, also cause
ichthyosis [18, 19]. Since the epoxyalcohols are metabo-
lized via x-hydroxylation to x-carboxy-acids, it is possible
that FALDH is necessary for their oxidation to biologically
active products and the ichthyosis in SLS may originate
from a block in this step [18].
Other pathogenic mechanisms associated with FALDH
deﬁciency may co-exist. Aliphatic aldehydes have the
propensity to react with molecules containing primary
amines, such as amino-containing lipids and lysine residues
in proteins. In SLS ﬁbroblasts, long-chain aldehydes form
covalent Schiff base adducts with phosphatidylethanol-
amine (PE) generating N-alkyl-phosphatidylethanolamine
[14]. The addition of the hydrophobic alkyl group to the
more polar ethanolamine moiety of PE is likely to perturb
its metabolism or proper incorporation into membrane
bilayers.
In summary, our ﬁndings prompt us to hypothesize that
the cutaneous pathogenesis of SLS originates from lipid
abnormalities in the SG that disrupt the normal formation
and secretion of LB, which consequently leads to inter-
cellular non-membranous lipid deposits in the SC, dimin-
ished SC membrane arrays and a defective water barrier.
Since the severity of cutaneous disease does not correlate
with neurologic symptoms in SLS [12], the pathogenic
mechanisms operating in the skin are almost certainly
distinct from those in the nervous system. Effective ther-
apeutic approaches in SLS will therefore likely depend on
impacting those pathogenic mechanisms that are uniquely
critical for each organ.
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